ACE-031

Overview

ACE-031 is a soluble form of the activin type IIB receptor (ActRIIB) fused to an IgG1 Fc domain. It functions as a decoy receptor, binding and neutralizing myostatin and other TGF-beta superfamily members that normally limit muscle growth. Originally developed by Acceleron Pharma for Duchenne muscular dystrophy (DMD), ACE-031 reached Phase 2 clinical trials before development was halted due to vascular side effects including nosebleeds and telangiectasia. In healthy volunteers, a single dose produced significant increases in lean mass and reductions in fat mass within 29 days.

Mechanism of action

ACE-031 acts as a ligand trap for members of the TGF-beta superfamily. By mimicking the extracellular domain of the ActRIIB receptor, it intercepts myostatin (GDF-8), activin A, activin B, and GDF-11 before they can bind cell-surface receptors and activate Smad2/3 signaling. Blocking this pathway removes the natural brake on muscle protein synthesis and satellite cell proliferation, resulting in rapid skeletal muscle hypertrophy. The Fc fusion domain extends circulating half-life through FcRn-mediated recycling and provides bivalent ligand binding.

Key research findings

• Significant lean mass increases (up to 1.7% in 29 days) observed in Phase 1 trials
• Simultaneous reduction in fat mass alongside muscle gains
• Long half-life (12-15 days) allows infrequent dosing
• Broad TGF-beta ligand neutralization for robust anti-catabolic effects
• Dose-dependent increases in thigh muscle volume confirmed by MRI

Research applications

Muscle Growth

• Muscle Hypertrophy — Phase 1 data showed statistically significant lean mass increases (average +1.7%) after a single IV dose in healthy postmenopausal women.
• Muscular Dystrophy — Phase 2 trial in DMD patients showed improvements in lean body mass and bone mineral density, but trial was halted due to vascular adverse events.
• Muscle Wasting / Cachexia — Preclinical models demonstrate robust prevention of muscle loss in disease states through myostatin pathway inhibition.

Body Composition

• Fat Loss — Phase 1 trial subjects showed concurrent fat mass reductions alongside lean mass gains, suggesting favorable nutrient partitioning.
• Bone Density — DMD trial data showed increases in bone mineral density, consistent with known effects of ActRIIB pathway modulation on bone metabolism.